Breast cancer treatment blocked for NHS use in England amid price issues
A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.
The National Institute for Health and Care Excellence (Nice) said the cost the NHS was being asked to pay for trastuzumab deruxtecan – sold under the brand name Enhertu – was “too high” in relation to its benefits.
The charity Breast Cancer Now has described the decision as a “dark day” for patients with the disease and urged manufacturer Daiichi Sankyo, which, to “come back to the table” with Nice and NHS England.
